Share Price and Basic Stock Data
Last Updated: October 2, 2025, 12:22 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Global Longlife Hospital and Research Ltd, with a current share price of ₹24.5 and a market capitalization of ₹25.7 Cr, exhibits a relatively low Price-to-Earnings ratio (P/E) and a healthy Return on Equity (ROE) of 17.7%. The company’s Return on Capital Employed (ROCE) stands at 13.7%, indicating efficient utilization of capital. With Promoters holding a significant stake of 54.90% and a debt-free balance sheet with zero borrowings, Global Longlife demonstrates strong financial discipline and stability. Additionally, the company’s Interest Coverage Ratio (ICR) of 3.10x suggests a comfortable ability to service its debt obligations.
Despite these strengths, Global Longlife Hospital faces risks such as a lower Price-to-Book Value (P/BV) ratio of 0.74x, potentially signaling undervaluation compared to industry peers. The Current Ratio, Cash Conversion Cycle (CCC) of 376.77 days, and relatively lower Net Profit margin of 0.20% warrant attention for liquidity and operational efficiency improvements. Looking ahead, diversifying revenue streams through strategic partnerships or expanding service offerings could enhance growth prospects, while macroeconomic factors impacting healthcare spending could pose a threat to the company’s financial performance.
In conclusion, Global Longlife Hospital and Research Ltd presents a mixed financial profile with strengths in profitability and capital management, alongside risks related to valuation and operational efficiency. Retail investors should closely monitor operational metrics and industry trends to make informed investment decisions in this healthcare sector player.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Global Longlife Hospital and Research Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.1 Cr. | 144 | 195/140 | 6.47 | 115 | 2.44 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 25.7 Cr. | 24.5 | 38.0/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 14.1 Cr. | 13.6 | 23.4/12.1 | 157 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 131 Cr. | 69.7 | 98.7/51.0 | 28.3 | 16.1 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 26.1 Cr. | 4.83 | 7.94/3.40 | 0.88 | 2.49 | 0.00 % | 79.2 % | 85.5 % | 10.0 |
| Industry Average | 28,753.57 Cr | 849.01 | 66.86 | 95.05 | 0.31% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Global Longlife Hospital and Research Ltd
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 12.87 | 11.80 | 11.70 | 12.33 | 1.18 | 0.58 | 0.00 |
| Expenses | 13.18 | 11.61 | 10.03 | 9.44 | 9.62 | 4.20 | 4.39 | 0.35 |
| Operating Profit | 6.76 | 1.26 | 1.77 | 2.26 | 2.71 | -3.02 | -3.81 | -0.35 |
| OPM % | 33.90% | 9.79% | 15.00% | 19.32% | 21.98% | -255.93% | -656.90% | |
| Other Income | 0.07 | 0.16 | 0.07 | 0.17 | 0.02 | 0.04 | 5.69 | -0.67 |
| Interest | 0.09 | 1.31 | 0.20 | 0.20 | 0.41 | 0.36 | 0.28 | 0.00 |
| Depreciation | 0.58 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.48 | 0.00 |
| Profit before tax | 6.16 | -0.46 | 1.06 | 1.64 | 1.71 | -3.98 | 1.12 | -1.02 |
| Tax % | 0.00% | -78.26% | 29.25% | 35.37% | 39.77% | -19.10% | -11.61% | 2.94% |
| Net Profit | 6.17 | -0.10 | 0.76 | 1.07 | 1.03 | -3.22 | 1.24 | -1.04 |
| EPS in Rs | 8.81 | -0.14 | 0.72 | 1.02 | 0.98 | -3.07 | 1.18 | -0.99 |
Last Updated: May 31, 2025, 5:54 am
Below is a detailed analysis of the quarterly data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.58 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Mar 2025, the value is 0.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.39 Cr. (Sep 2024) to 0.35 Cr., marking a decrease of 4.04 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.35 Cr.. The value appears strong and on an upward trend. It has increased from -3.81 Cr. (Sep 2024) to -0.35 Cr., marking an increase of 3.46 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -656.90% (Sep 2024) to 0.00%, marking an increase of 656.90%.
- For Other Income, as of Mar 2025, the value is -0.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.69 Cr. (Sep 2024) to -0.67 Cr., marking a decrease of 6.36 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.28 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.28 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.48 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.48 Cr..
- For Profit before tax, as of Mar 2025, the value is -1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.12 Cr. (Sep 2024) to -1.02 Cr., marking a decrease of 2.14 Cr..
- For Tax %, as of Mar 2025, the value is 2.94%. The value appears to be increasing, which may not be favorable. It has increased from -11.61% (Sep 2024) to 2.94%, marking an increase of 14.55%.
- For Net Profit, as of Mar 2025, the value is -1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.24 Cr. (Sep 2024) to -1.04 Cr., marking a decrease of 2.28 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.99. The value appears to be declining and may need further review. It has decreased from 1.18 (Sep 2024) to -0.99, marking a decrease of 2.17.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:02 pm
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 33.44 | 33.32 | 32.70 | 32.44 | 23.38 | 13.46 | 0.31 |
| Expenses | 26.61 | 29.88 | 27.26 | 24.14 | 19.30 | 13.68 | 4.45 |
| Operating Profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.08 | -0.22 | -4.14 |
| OPM % | 20.42% | 10.32% | 16.64% | 25.59% | 17.45% | -1.63% | -1,335.48% |
| Other Income | 0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.00 | 5.02 |
| Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.45 | 0.80 | 0.30 |
| Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 0.48 |
| Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.70 | -2.27 | 0.10 |
| Tax % | 49.07% | -18.69% | -16.57% | 37.30% | 32.59% | -3.52% | -100.00% |
| Net Profit | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | 0.20 |
| EPS in Rs | 1.94 | -1.23 | 2.93 | 5.10 | 1.74 | -2.09 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -163.24% | 338.37% | 74.15% | -48.74% | -219.67% | 109.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 501.61% | -264.23% | -122.89% | -170.93% | 328.80% |
Global Longlife Hospital and Research Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -61% |
| 3 Years: | -79% |
| TTM: | -98% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -119% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -33% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -4% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: August 11, 2025, 4:04 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 10.50 | 10.50 | 10.50 |
| Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.29 |
| Borrowings | 27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | 0.00 |
| Other Liabilities | 3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.06 |
| Total Liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 |
| Fixed Assets | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 1.03 | 0.00 | 0.00 |
| Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 0.03 |
| Other Assets | 23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 26.82 |
| Total Assets | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 |
Below is a detailed analysis of the balance sheet data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.50 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.50 Cr..
- For Reserves, as of Mar 2025, the value is 16.29 Cr.. The value appears strong and on an upward trend. It has increased from 15.43 Cr. (Mar 2024) to 16.29 Cr., marking an increase of 0.86 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 12.74 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 12.74 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing). It has decreased from 3.07 Cr. (Mar 2024) to 0.06 Cr., marking a decrease of 3.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 26.85 Cr.. The value appears to be improving (decreasing). It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.27 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 17.27 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.03 Cr..
- For Other Assets, as of Mar 2025, the value is 26.82 Cr.. The value appears strong and on an upward trend. It has increased from 24.44 Cr. (Mar 2024) to 26.82 Cr., marking an increase of 2.38 Cr..
- For Total Assets, as of Mar 2025, the value is 26.85 Cr.. The value appears to be declining and may need further review. It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..
Notably, the Reserves (16.29 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.35 | -20.07 | -11.60 | -0.39 | -5.21 | -12.96 | -4.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 94.85 | 68.68 | 87.51 | 100.25 | 151.43 | 52.88 | 376.77 |
| Inventory Days | 169.49 | 157.97 | 34.46 | 88.98 | 69.12 | 131.64 | 0.00 |
| Days Payable | 229.91 | 391.69 | 138.68 | 432.74 | 110.43 | 765.90 | |
| Cash Conversion Cycle | 34.44 | -165.03 | -16.71 | -243.52 | 110.13 | -581.38 | 376.77 |
| Working Capital Days | 19.21 | 12.16 | 7.14 | -29.70 | 344.86 | -238.36 | 1,283.39 |
| ROCE % | 3.81% | 12.75% | 26.22% | 6.35% | -2.51% | -13.69% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Diluted EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Cash EPS (Rs.) | 0.64 | -0.89 | 2.85 | 6.74 | 5.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Revenue From Operations / Share (Rs.) | 0.54 | 12.87 | 22.38 | 46.88 | 46.72 |
| PBDIT / Share (Rs.) | 0.81 | -0.23 | 4.07 | 11.79 | 8.67 |
| PBIT / Share (Rs.) | 0.35 | -1.43 | 2.96 | 10.15 | 5.98 |
| PBT / Share (Rs.) | 0.09 | -2.16 | 2.58 | 8.16 | 2.51 |
| Net Profit / Share (Rs.) | 0.18 | -2.08 | 1.74 | 5.11 | 2.92 |
| PBDIT Margin (%) | 148.50 | -1.83 | 18.18 | 25.14 | 18.56 |
| PBIT Margin (%) | 65.02 | -11.08 | 13.22 | 21.66 | 12.81 |
| PBT Margin (%) | 17.18 | -16.76 | 11.52 | 17.40 | 5.37 |
| Net Profit Margin (%) | 34.41 | -16.19 | 7.77 | 10.89 | 6.25 |
| Return on Networth / Equity (%) | 0.74 | -8.43 | 2.84 | 21.06 | 14.96 |
| Return on Capital Employeed (%) | 1.39 | -5.09 | 4.56 | 35.19 | 15.94 |
| Return On Assets (%) | 0.74 | -5.24 | 2.40 | 10.51 | 5.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.13 | 0.05 | 0.16 | 0.91 |
| Total Debt / Equity (X) | 0.00 | 0.49 | 0.14 | 0.51 | 0.91 |
| Asset Turnover Ratio (%) | 0.01 | 0.22 | 0.42 | 0.92 | 0.85 |
| Current Ratio (X) | 0.00 | 0.31 | 4.28 | 0.82 | 1.13 |
| Quick Ratio (X) | 0.00 | 0.28 | 4.17 | 0.75 | 1.06 |
| Inventory Turnover Ratio (X) | 8.36 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.10 | -0.32 | 10.67 | 5.90 | 2.50 |
| Interest Coverage Ratio (Post Tax) (X) | 1.72 | -1.85 | 5.56 | 3.55 | 1.84 |
| Enterprise Value (Cr.) | -1.58 | 53.35 | 52.71 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | -2.74 | 3.95 | 2.24 | 0.00 | 0.00 |
| EV / EBITDA (X) | -1.85 | -215.57 | 12.33 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 34.48 | 3.03 | 2.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.74 | 1.58 | 0.73 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 34.54 | 3.03 | 2.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | -0.05 | 0.03 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Longlife Hospital and Research Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 3. It has increased from -0.89 (Mar 24) to 0.64, marking an increase of 1.53.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.54. It has decreased from 12.87 (Mar 24) to 0.54, marking a decrease of 12.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 2. It has increased from -0.23 (Mar 24) to 0.81, marking an increase of 1.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from -1.43 (Mar 24) to 0.35, marking an increase of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from -2.16 (Mar 24) to 0.09, marking an increase of 2.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has increased from -2.08 (Mar 24) to 0.18, marking an increase of 2.26.
- For PBDIT Margin (%), as of Mar 25, the value is 148.50. This value is within the healthy range. It has increased from -1.83 (Mar 24) to 148.50, marking an increase of 150.33.
- For PBIT Margin (%), as of Mar 25, the value is 65.02. This value exceeds the healthy maximum of 20. It has increased from -11.08 (Mar 24) to 65.02, marking an increase of 76.10.
- For PBT Margin (%), as of Mar 25, the value is 17.18. This value is within the healthy range. It has increased from -16.76 (Mar 24) to 17.18, marking an increase of 33.94.
- For Net Profit Margin (%), as of Mar 25, the value is 34.41. This value exceeds the healthy maximum of 10. It has increased from -16.19 (Mar 24) to 34.41, marking an increase of 50.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 15. It has increased from -8.43 (Mar 24) to 0.74, marking an increase of 9.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.39. This value is below the healthy minimum of 10. It has increased from -5.09 (Mar 24) to 1.39, marking an increase of 6.48.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has increased from -5.24 (Mar 24) to 0.74, marking an increase of 5.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.00, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.49 (Mar 24) to 0.00, marking a decrease of 0.49.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.22 (Mar 24) to 0.01, marking a decrease of 0.21.
- For Current Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1.5. It has decreased from 0.31 (Mar 24) to 0.00, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 0.28 (Mar 24) to 0.00, marking a decrease of 0.28.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.36. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 8.36, marking an increase of 8.36.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.10. This value is within the healthy range. It has increased from -0.32 (Mar 24) to 3.10, marking an increase of 3.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 3. It has increased from -1.85 (Mar 24) to 1.72, marking an increase of 3.57.
- For Enterprise Value (Cr.), as of Mar 25, the value is -1.58. It has decreased from 53.35 (Mar 24) to -1.58, marking a decrease of 54.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -2.74. This value is below the healthy minimum of 1. It has decreased from 3.95 (Mar 24) to -2.74, marking a decrease of 6.69.
- For EV / EBITDA (X), as of Mar 25, the value is -1.85. This value is below the healthy minimum of 5. It has increased from -215.57 (Mar 24) to -1.85, marking an increase of 213.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 34.48. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.48, marking an increase of 31.45.
- For Price / BV (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.58 (Mar 24) to 0.74, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 34.54. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.54, marking an increase of 31.51.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.01, marking an increase of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Longlife Hospital and Research Ltd:
- Net Profit Margin: 34.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.39% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 66.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 34.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad Gujarat 380059 | investor@globalhospital.co.in http://www.globalhospital.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhruv Jani | Managing Director |
| Ms. Hetal Thakkar | Executive Director & CFO |
| Mrs. Sucheta Jani | Non Executive Director |
| Mr. Manasvi Thapar | Independent Director |
| Mr. Sandeep Shah | Independent Director |
FAQ
What is the intrinsic value of Global Longlife Hospital and Research Ltd?
Global Longlife Hospital and Research Ltd's intrinsic value (as of 09 October 2025) is 55.25 which is 125.51% higher the current market price of 24.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹25.7 Cr. market cap, FY2025-2026 high/low of 38.0/0.00, reserves of ₹16.29 Cr, and liabilities of 26.85 Cr.
What is the Market Cap of Global Longlife Hospital and Research Ltd?
The Market Cap of Global Longlife Hospital and Research Ltd is 25.7 Cr..
What is the current Stock Price of Global Longlife Hospital and Research Ltd as on 09 October 2025?
The current stock price of Global Longlife Hospital and Research Ltd as on 09 October 2025 is 24.5.
What is the High / Low of Global Longlife Hospital and Research Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Global Longlife Hospital and Research Ltd stocks is 38.0/0.00.
What is the Stock P/E of Global Longlife Hospital and Research Ltd?
The Stock P/E of Global Longlife Hospital and Research Ltd is .
What is the Book Value of Global Longlife Hospital and Research Ltd?
The Book Value of Global Longlife Hospital and Research Ltd is 25.5.
What is the Dividend Yield of Global Longlife Hospital and Research Ltd?
The Dividend Yield of Global Longlife Hospital and Research Ltd is 0.00 %.
What is the ROCE of Global Longlife Hospital and Research Ltd?
The ROCE of Global Longlife Hospital and Research Ltd is 13.7 %.
What is the ROE of Global Longlife Hospital and Research Ltd?
The ROE of Global Longlife Hospital and Research Ltd is 17.7 %.
What is the Face Value of Global Longlife Hospital and Research Ltd?
The Face Value of Global Longlife Hospital and Research Ltd is 10.0.